| 2022-07-26 4:31:19 am |
Brooklyn ImmunoTherapeutics Announces Results of Phase 2 Study of IRX-2 in Head and Neck Cancer |
GlobeNewsWire |
| Jun-17-22 05:00PM |
Brooklyn ImmunoTherapeutics Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency |
GlobeNewswire |
| Jun-07-22 07:30AM |
Brooklyn ImmunoTherapeutics Announces Board Changes |
GlobeNewswire |
| May-31-22 07:30AM |
Brooklyn ImmunoTherapeutics Announces Changes to Executive Management: Matt Angel, Ph.D. Appointed Interim Chief Executive Officer and President, Andrew Jackson Appointed Chief Financial Officer Postpones 2022 Annual Meeting |
GlobeNewswire |
| May-27-22 04:30PM |
Brooklyn ImmunoTherapeutics Announces Receipt of Notice from Nasdaq Regarding Delayed Filing of Quarterly Report on Form 10-Q |
GlobeNewswire |
| May-19-22 08:23AM |
Amarin Announces Appointment of New Directors and Board Leadership Changes |
GlobeNewswire |
| Apr-21-22 07:30AM |
Brooklyn ImmunoTherapeutics Announces Establishment of New Research and Development Facility for Advancement of Engineered Cellular Medicines |
GlobeNewswire |
| Apr-15-22 04:15PM |
Brooklyn ImmunoTherapeutics Announces Fourth Quarter and Full Year 2021 Financial Results |
GlobeNewswire |
| Mar-09-22 04:15PM |
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million Private Placement |
GlobeNewswire |
| Mar-07-22 08:00AM |
Brooklyn ImmunoTherapeutics Announces $12 Million Private Placement |
GlobeNewswire |
| Jan-27-22 05:38PM |
Cypress Point Wealth Management, LLC Buys Brooklyn ImmunoTherapeutics Inc, Robinhood Markets ... |
GuruFocus.com |
| Jan-20-22 07:30AM |
Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board of Directors |
GlobeNewswire |
| Jan-13-22 08:30AM |
Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Property Portfolio |
GlobeNewswire |
| Dec-17-21 08:00AM |
Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index |
GlobeNewswire |
| Dec-14-21 08:47AM |
Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index |
GlobeNewswire |
| Dec-02-21 08:00AM |
Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences |
GlobeNewswire |
| Nov-29-21 08:00AM |
Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Quality |
GlobeNewswire |
| Nov-19-21 06:00AM |
Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Secondary Offering of Shares Issued in Previously Announced Novellus Acquisition |
GlobeNewswire |
| Nov-09-21 04:35PM |
Brooklyn ImmunoTherapeutics Announces Third Quarter 2021 Financial Results |
GlobeNewswire |
| Oct-27-21 07:05AM |
What Kind Of Investors Own Most Of Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX)? |
Simply Wall St. |
| Oct-14-21 04:15PM |
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to Nasdaq |
GlobeNewswire |
| Oct-07-21 10:11PM |
Investing in These 2 Stocks Could Double Your Money, Say Analysts |
TipRanks |
| Sep-23-21 04:30PM |
Brooklyn ImmunoTherapeutics Reports Inducement Grants |
GlobeNewswire |
| Sep-22-21 10:07AM |
Brooklyn ImmunoTherapeutics Appoints Roger Sidhu, M.D. as Chief Medical Officer |
GlobeNewswire |
| Sep-21-21 08:30AM |
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from September 20, 2021 |
GlobeNewswire |
| Sep-15-21 08:15AM |
Factor Bioscience Celebrates 10th Anniversary with Grand Opening of ISO Class 7 Cleanroom Facility in Cambridge, Massachusetts |
PR Newswire |
| Sep-13-21 08:00AM |
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Monday, September 20, 2021, at 4:30 PM ET |
GlobeNewswire |
| Sep-09-21 08:30AM |
Brooklyn ImmunoTherapeutics to Participate in Grand Opening of Cambridge-Based mRNA Cleanroom Facility Shared with Factor Bioscience |
GlobeNewswire |
| Aug-20-21 04:15PM |
Brooklyn ImmunoTherapeutics Announces Adjournment of Annual Meeting of Stockholders Due to Lack of Quorum |
GlobeNewswire |
| Aug-20-21 08:30AM |
Brooklyn ImmunoTherapeutics Provides Highlights of Shareholder Update Call from August 19, 2021 |
GlobeNewswire |
| Aug-16-21 04:15PM |
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call on Thursday, August 19, 2021 at 4:30 PM ET |
GlobeNewswire |
| Aug-16-21 08:30AM |
Keynotes, Educational Panels and 60 Companies to Present at the SNN Network Summer Virtual Event on August 17-19, 2021 |
ACCESSWIRE |
| Aug-16-21 07:00AM |
Brooklyn ImmunoTherapeutics Announces Second Quarter 2021 Financial Results |
GlobeNewswire |
| Aug-13-21 02:22PM |
Brooklyn ImmunoTherapeutics to Present at the SNN Virtual Investor Conference on August 18, 2021 |
GlobeNewswire |
| Jul-23-21 04:30PM |
Brooklyn Immuno Reports Inducement Grants |
GlobeNewswire |
| Jul-19-21 08:00AM |
Brooklyn ImmunoTherapeutics Completes Acquisition of Novellus Therapeutics |
GlobeNewswire |
| Jul-13-21 08:15AM |
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief Administrative Officer |
GlobeNewswire |
| Jul-12-21 08:15AM |
Brooklyn ImmunoTherapeutics to Present at the Access to Giving Virtual Investor Conference on July 15, 2021 |
GlobeNewswire |
| Jul-08-21 11:20AM |
50+ Companies to Present at the Access to Giving Virtual Investor Conference on July 13th - 15th, 2021 |
ACCESSWIRE |
| Jul-06-21 05:57PM |
Brooklyn ImmunoTherapeutics Reports Inducement Grants |
GlobeNewswire |
| Jun-14-21 07:30AM |
Brooklyn ImmunoTherapeutics Executes Letter of Intent to Acquire Novellus Therapeutics |
GlobeNewswire |
| Jun-09-21 07:30AM |
Brooklyn ImmunoTherapeutics Set to Join Russell 3000 Index |
GlobeNewswire |
| Jun-08-21 07:30AM |
Brooklyn ImmunoTherapeutics Welcomes Dr. Kevin A. DAmour as Chief Scientific Officer |
GlobeNewswire |
| Jun-02-21 08:00AM |
Brooklyn ImmunoTherapeutics Establishes Research and Development Center in Cambridge, Massachusetts |
GlobeNewswire |
| May-26-21 02:03PM |
Brooklyn ImmunoTherapeutics CEO Howard J. Federoff Provides Roadmap for the Companys Future During May 25, 2021 Shareholder Update Call |
Business Wire |
| May-24-21 02:58PM |
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed mRNA Technology Platform with $20M Financing |
Business Wire |
| May-21-21 07:30AM |
Michael Andreeff, M.D., Ph.D to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics, Inc. |
Business Wire |
| May-18-21 07:30AM |
Brooklyn ImmunoTherapeutics to Conduct Shareholder Update Conference Call Tuesday May 25, 2021 at 4:30 PM ET |
Business Wire |
| May-11-21 07:30AM |
Brooklyn ImmunoTherapeutics Announces Publication of Results of IRX-2 Monotherapy in Early Stage Breast Cancer in Breast Cancer Research |
Business Wire |
| May-07-21 07:30AM |
Erich Mohr, Ph.D., to Join the Board of Directors of Brooklyn ImmunoTherapeutics |
Business Wire |
| Apr-29-21 07:30AM |
Brooklyn ImmunoTherapeutics Acquires License for mRNA Technology Platform to Develop Genetically Edited Cells to Treat Multiple Cancers, Blood and Other Disorders |
Business Wire |
| Apr-26-21 07:30AM |
Matthew During, M.D., Ph.D. to Join the Scientific Advisory Board of Brooklyn ImmunoTherapeutics |
Business Wire |
| Apr-19-21 04:10PM |
Brooklyn ImmunoTherapeutics Reports Inducement Grants |
Business Wire |
| Apr-15-21 04:10PM |
Brooklyn ImmunoTherapeutics Pays $1 Million Towards Acquisition of License for mRNA Technology Platform to Develop Genetically Edited Cells for Multiple Cancers and Blood Disorders |
Business Wire |
| Apr-15-21 08:00AM |
Dennis H. Langer, M.D., J.D. to Join the Board of Directors of Brooklyn ImmunoTherapeutics, Inc. |
Business Wire |
| Apr-06-21 08:00AM |
Howard J. Federoff, MD, PhD Appointed Chief Executive Officer of Brooklyn ImmunoTherapeutics, Inc. |
Business Wire |
| Mar-25-21 05:20PM |
Brooklyn ImmunoTherapeutics Completes Reverse Merger with NTN Buzztime |
Business Wire |
| Dec-14-20 08:44AM |
Is the Options Market Predicting a Spike in Lineage Cell Therapeutics (LCTX) Stock? |
Zacks |
| Nov-04-20 06:05PM |
Lineage Cell (LCTX) Reports Q3 Loss, Lags Revenue Estimates |
Zacks |
| May-08-20 10:37PM |
Edited Transcript of BTX earnings conference call or presentation 7-May-20 8:30pm GMT |
Thomson Reuters StreetEvents |